Tag Archives: Ewing Sarcoma

April, 2017

  • 10 April

    FDA Grants Orphan Drug Status to NantCell’s Ganitumab in Ewing Sarcoma

    CULVER CITY, Calif.–(BUSINESS WIRE)–NantCell, Inc., part of the NantWorks ecosystem of companies, announced today that the FDA has granted Orphan Drug Designation to the company’s Ganitumab, Insulin Growth Factor-1R (IGF-1R) monoclonal antibody therapy for the treatment of patients with Ewing sarcoma. Ganitumab is a fully human monoclonal antibody directed against IGF-1R that is being investigated …

June, 2016